左西孟旦促进严重心源性休克患者脱离ECMO:LEVOECMO随机临床试验
LEVOECMO是一项在法国11个ICU开展的双盲安慰剂对照随机试验,纳入205例启动VA-ECMO 48小时内的急性心源性休克成人患者,1:1接受左西孟旦0.15 μg/kg/min(2小时后增至0.20 μg/kg/min)或安慰剂。30天内成功脱离ECMO比例两组均为68.3%(风险差0.0%,95%CI -12.8%至12.7%;亚分布HR 1.02,95%CI 0.74-1.39;P=0.92)。ECMO时长、ICU住院时间及60天死亡率均无显著差异,左西孟旦组室性心律失常更常见(17.8% vs 8.7%)。
要点
- 严重但可能可逆心源性休克的VA-ECMO成人患者,早期左西孟旦30天内成功脱离ECMO比例68.3% vs 安慰剂68.3%,无显著差异(P=0.92)。
- 左西孟旦组室性心律失常发生率17.8% vs 安慰剂8.7%,绝对风险差9.2%(95%CI 0.4%-18.1%)。
- 两组60天死亡率27.7% vs 25.0%,无显著差异(风险差2.7%,95%CI -9.0%至15.3%;P=0.78)。
- ECMO中位时长左西孟旦组5天(IQR 4-7)vs 安慰剂组6天(IQR 4-11),无显著差异(P=0.53)。
适用人群与场景
- 法国11个ICU纳入的成人急性心源性休克患者,启动VA-ECMO在48小时内,病情严重但可能可逆。
- 主要病因包括心脏术后79例(38.5%)、急性心肌梗死56例(27.3%)、心肌炎28例(13.7%)。
处置流程与药物剂量
- 左西孟旦组:0.15 μg/kg/min起始,2小时后增至0.20 μg/kg/min持续输注;93%患者剂量增至0.20±0.01 μg/kg/min。
- 安慰剂组:96%患者剂量增至0.20±0.01 μg/kg/min。
研究设计与关键结果
- 随机双盲安慰剂对照试验,11个ICU,205例(左西孟旦101例、安慰剂104例),中位年龄58岁(IQR 50-67),男性149例(72.7%)。
- 主要终点30天内成功脱离ECMO:左西孟旦组69/101(68.3%)vs 安慰剂组71/104(68.3%),风险差0.0%(95%CI -12.8%至12.7%),亚分布HR 1.02(95%CI 0.74-1.39),P=0.92。
- ECMO中位时长:左西孟旦组5天(IQR 4-7)vs 安慰剂组6天(IQR 4-11),P=0.53。
- ICU平均住院时间:左西孟旦组18天(SD 15)vs 安慰剂组19天(SD 15),P=0.42。
- 60天死亡率:左西孟旦组27.7% vs 安慰剂组25.0%,风险差2.7%(95%CI -9.0%至15.3%),P=0.78。
- 室性心律失常:左西孟旦组18例(17.8%)vs 安慰剂组9例(8.7%),绝对风险差9.2%(95%CI 0.4%-18.1%)。
证据类型、等级与局限
- 证据类型:随机、双盲、安慰剂对照临床试验。
- 局限:原文未报告局限性。
对床旁实践的改变
- 对于严重但可能可逆心源性休克并启动VA-ECMO 48小时内的成人患者,早期使用左西孟旦未能显著缩短30天内成功脱离ECMO的时间,且室性心律失常发生更频繁。
- 原文结论未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
IMPORTANCE: Levosimendan may facilitate weaning from venoarterial extracorporeal membrane oxygenation (VA-ECMO) and improve survival, but supporting evidence remains limited.
OBJECTIVE: To assess whether early administration of levosimendan reduces the time to successful VA-ECMO weaning in patients with severe but potentially reversible cardiogenic shock.
DESIGN, SETTING, AND PARTICIPANTS: Randomized, double-blind, placebo-controlled trial conducted across 11 intensive care units (ICUs) in France. Between August 27, 2021, and September 10, 2024, 205 adult patients with acute cardiogenic shock who had started VA-ECMO in the preceding 48 hours were enrolled. Final follow-up was completed on November 10, 2024.
INTERVENTIONS: Patients were randomized in a 1:1 ratio to receive levosimendan, 0.15 μg/kg per minute, to be increased to 0.20 μg/kg per minute after 2 hours (n = 101), or placebo (n = 104).
MAIN OUTCOMES AND MEASURES: The primary outcome was time to successful ECMO weaning within 30 days following randomization. Secondary outcomes included ECMO-, mechanical ventilation-, and organ failure-free days, ICU and hospital lengths of stay, serious adverse events, and all-cause 30- and 60-day mortality.
RESULTS: Among the 205 randomized patients (median age, 58 [IQR, 50-67] years; 149 [72.7%] male), main cardiogenic shock etiologies were postcardiotomy (79 [38.5%]), acute myocardial infarction (56 [27.3%]), and myocarditis (28 [13.7%]). Treatment dose was increased to 0.20 ± 0.01 μg/kg per minute in 93% of patients receiving levosimendan and in 96% of those receiving placebo. Within 30 days, 69 of 101 patients (68.3%) had a successful ECMO weaning in the levosimendan group compared with 71 of 104 (68.3%) in the placebo group (risk difference, 0.0% [95% CI, -12.8% to 12.7%]; subdistribution hazard ratio, 1.02 [95% CI, 0.74-1.39]; P = .92). In the levosimendan and placebo groups, respectively, median ECMO duration (5 [IQR, 4-7] days vs 6 [IQR, 4-11] days; P = .53), mean ICU length of stay (18 [SD, 15] days vs 19 [SD, 15] days; P = .42), and 60-day mortality (27.7% vs 25.0%; risk difference, 2.7% [95% CI, -9.0% to 15.3%]; P = .78) did not differ significantly. Ventricular arrhythmias occurred more frequently with levosimendan (18 [17.8%] vs 9 [8.7%]; absolute risk difference, 9.2% [95% CI, 0.4%-18.1%]).
CONCLUSIONS AND RELEVANCE: Among patients with severe but potentially reversible cardiogenic shock supported by VA-ECMO, early levosimendan administration did not significantly reduce the time to successful weaning of ECMO compared with placebo.
TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT04728932.
参考来源
- Combes A, Saura O, Nesseler N, et al. Levosimendan to Facilitate Weaning From ECMO in Patients With Severe Cardiogenic Shock: The LEVOECMO Randomized Clinical Trial. JAMA. 2026. PMID: 41324946. doi:10.1001/jama.2025.19843
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。